Severe, persistent pain in the upper abdomen — often boring through to the back — with nausea and vomiting that will not stop. That is the pancreatitis pattern.
Stop and seek medical assessment. Persistent vomiting also dehydrates and strains the kidneys — sip fluids.
Unrelenting abdominal pain, repeated vomiting, or signs of dehydration → urgent care or ER. And tell any anaesthetist before surgery: these drugs slow stomach emptying and raise the risk of aspiration under anaesthesia.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
Semaglutide is a long-acting analog of glucagon-like peptide-1. It binds the GLP-1 receptor, a class B GPCR expressed on pancreatic beta cells, and potentiates glucose-dependent insulin secretion while suppressing glucagon release. Structural modification — an Aib substitution at position 8 resisting DPP-4 cleavage, plus a C18 fatty diacid that drives reversible albumin binding — extends half-life to roughly one week. Central GLP-1 receptors in the hypothalamus and hindbrain mediate reduced appetite and energy intake; gastric emptying is slowed.
Among the most extensively studied peptides in medicine. The SUSTAIN programme established glycaemic efficacy in type 2 diabetes, STEP established weight reduction in obesity, and SELECT reported cardiovascular outcome benefit in patients with established cardiovascular disease and overweight or obesity. Evidence base spans tens of thousands of randomised participants.
FDA-approved. Marketed for type 2 diabetes, chronic weight management, and cardiovascular risk reduction depending on the specific product. Prescription-only. FDA issued a large volume of warning letters during 2025 to entities marketing compounded or research-labelled semaglutide.
Boxed warning for thyroid C-cell tumours observed in rodents; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2. Common gastrointestinal effects. Signals for pancreatitis, gallbladder disease, and (with rapid loss) lean mass reduction. Requires physician supervision.
Titrated from a sub-therapeutic 0.25 mg to limit nausea. Type 2 diabetes (Ozempic): up to 1–2 mg once weekly SC. Weight management (Wegovy): 2.4 mg once weekly SC. Oral (Rybelsus): 7 or 14 mg once daily. FDA-label regimens, titrated and monitored by a prescriber.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.